| Title |
Targeting hedgehog signaling in cancer: research and clinical developments
|
|---|---|
| Published in |
OncoTargets and therapy, October 2013
|
| DOI | 10.2147/ott.s34678 |
| Pubmed ID | |
| Authors |
Jingwu Xie, Christopher M Bartels, Scott W Barton, Dongsheng Gu |
| Abstract |
Since its first description in Drosophila by Drs Nusslein-Volhard and Wieschaus in 1980, hedgehog (Hh) signaling has been implicated in regulation of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and carcinogenesis. The first link of Hh signaling to cancer was established through studies of Gorlin syndrome in 1996 by two independent teams. Later, it was shown that Hh signaling may be involved in many types of cancer, including skin, leukemia, lung, brain, and gastrointestinal cancers. In early 2012, the US Food and Drug Administration approved the clinical use of Hh inhibitor Erivedge/vismodegib for treatment of locally advanced and metastatic basal cell carcinomas. With further investigation, it is possible to see more clinical applications of Hh signaling inhibitors. In this review, we will summarize major advances in the last 3 years in our understanding of Hh signaling activation in human cancer, and recent developments in preclinical and clinical studies using Hh signaling inhibitors. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | 2% |
| Unknown | 83 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 19% |
| Researcher | 15 | 18% |
| Student > Ph. D. Student | 14 | 16% |
| Student > Bachelor | 9 | 11% |
| Professor | 6 | 7% |
| Other | 16 | 19% |
| Unknown | 9 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 30 | 35% |
| Medicine and Dentistry | 26 | 31% |
| Biochemistry, Genetics and Molecular Biology | 10 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Chemistry | 3 | 4% |
| Other | 1 | 1% |
| Unknown | 12 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2020.
All research outputs
#7,778,730
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#417
of 3,016 outputs
Outputs of similar age
#66,395
of 219,852 outputs
Outputs of similar age from OncoTargets and therapy
#9
of 34 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 219,852 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.